



21st October 2009

Companies Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT / MEDIA RELEASE

ENTITLEMENT ISSUE UPDATE

The Board of Anteo Diagnostics Limited (“ADO”) is pleased to announce that it has closed its recent Underwritten Non Renounceable Entitlement Offer (“the Offer”) effective the 20th October 2009.

Applications for Entitlement and Shortfall shares have been received for a total of 144,121,521 shares representing application monies of approximately \$864,729. The Company together with its share registry are in the processing of finalising cleared funds and reconciling the final position.

The Underwriter and the Company will work together to complete the final applicant listing over the coming days.

The Company will keep the market fully updated as it finalises the Offer.

For further information please contact:

Dr Geoff Cumming, CEO, Anteo Diagnostics Limited
Tel: +612 8823 3110

Mr James Henderson, Non Executive Chairman, Anteo Diagnostics Limited
Tel: +612 8823 3100

About Anteo

Anteo Diagnostics is an Australian company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and the use of those coatings in biomarker development. Anteo's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. Anteo applies its coatings to develop novel biomarkers for a range of diseases. Anteo works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.anteodx.com.

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com

For personal use only